Form 8-K - Current report:
SEC Accession No. 0001501697-25-000008
Filing Date
2025-08-25
Accepted
2025-08-25 08:12:48
Documents
12
Period of Report
2025-08-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20250822.htm   iXBRL 8-K 26936
  Complete submission text file 0001501697-25-000008.txt   147708

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20250822.xsd EX-101.SCH 1785
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20250822_lab.xml EX-101.LAB 23449
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20250822_pre.xml EX-101.PRE 13583
14 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20250822_htm.xml XML 2824
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 251247964
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)